GSK3B and myotonic dystrophy type 1: While the increase in active GSK3β in PBMCs from patients with DM1 correlates with muscle weakness (Figure 3), it is also essential to determine if the pathological increase of active GSK3β in PBMCs correlates with the severity of brain atrophy in DM1 and with other symptoms such as cardiac defects and insulin resistance.